Open AccessCurrent status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications
Author(s) -
Stavros Spiliοpoulos,
Georgios Pastromas
Publication year - 2015
Publication title -
world journal of cardiology
Language(s) - English
Resource type - Journals
ISSN - 1949-8462
DOI - 10.4330/wjc.v7.i12.912
Subject(s) - medicine , clopidogrel , aspirin , peripheral , cardiology , platelet , arterial disease , revascularization , clinical trial , disease , ex vivo , platelet aggregation inhibitor , intensive care medicine , myocardial infarction , in vivo , vascular disease , microbiology and biotechnology , biology
Antiplatelet therapy with aspirin or clopidogrel or both is the standard care for patients with proven coronary or peripheral arterial disease, especially those undergoing endovascular revascularization procedures. However, despite the administration of the antiplatelet regiments, some patients still experience recurrent cardiovascular ischemic events. So far, it is well documented by several studies that in vitro response of platelets may be extremely variable. Poor antiplatelet effect of clopidogrel or high on-treatment platelet reactivity (HTPR) is under investigation by numerous recent studies. This review article focuses on methods used for the ex vivo evaluation of HTPR, as well as on the possible underlying mechanisms and the clinical consequences of this entity. Alternative therapeutic options and future directions are also addressed.